A 'renaissance in neuroscience' could deliver a fresh crop of psychiatric medicines

After two decades, the biggest names in the global drug industry appear to be coming back to the table. The need for new, effective psychiatric treatments has only grown, and scores of biotech startups have been toiling in pharma's absence. Now, through a combination of scientific discovery and a little serendipity, the field has finally come up with a spate of promising new medicines. Read more.

By Damian Garde

Adobe

Exclusive: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show

Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a contentious dispute between one of its most powerful researchers and a junior scientist over authorship, credit, and charges of verbal abuse. High-ranking officials at the cancer center tried — and failed — to resolve the feud, and documents obtained by STAT shed new light on the deep divisions at the heart of this case. Read more.

By Angus Chen

Giannis Papanikos/AP

Pfizer is about to make a big push in cancer. Will investors listen?

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution. Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. Read more.

By Matthew Herper

More great reads from STAT this week

FDA protocols originally intended to be extra conservative are now heralded as evidence of mifepristone's risk
Opinion: IVF bans like Alabama's could cost the lives of children already born
Why do some women experience UTI pain with no clear infection? A mouse study offers clues

More around STAT